BENEFIT 11: No new safety signals with interferon beta-1b

NEW ORLEANS – The long-term safety of interferon beta-1b for the treatment of multiple sclerosis is well established, and 11-year outcomes from the randomized, placebo-controlled BENEFIT trial...
Source: Clinical Neurology News - Category: Neurology Source Type: news